Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome

Cancer Genetics

Volumn 205, Issue 6, 2012, Pages 285-294

  Dambruoso, Irene ^a   Boni, Marina ^a   Rossi, Marianna ^a   Zappasodi, Patrizia ^a   Calvello, Celeste ^a   Zappatore, Rita ^a   Cavigliano, Paola Maria ^a   Giardini, Ilaria ^a   Rocca, Barbara ^a   Caresana, Marilena ^a   Astori, Cesare ^a   Cazzola, Mario ^a   Castagnola, Carlo ^a   Bernasconi, Paolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Conventional cytogenetics; FISH; MDS; TET2

Indexed keywords

TEN ELEVEN TRANSLOCATION 2 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CHROMOSOME 1P; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME ANALYSIS; CHROMOSOME ARM; CHROMOSOME BAND; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME INSERTION; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 4; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE LOCUS; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; STRUCTURAL CHROMOSOME ABERRATION; TET2 GENE; TUMOR SUPPRESSOR GENE; ANEUPLOIDY; CHROMOSOME 4; CHROMOSOME BANDING PATTERN; GENE TRANSLOCATION; GENETICS; HAPLOINSUFFICIENCY; KARYOTYPING; METHODOLOGY; MIDDLE AGED;

BACTERIA (MICROORGANISMS);

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 4; DNA-BINDING PROTEINS; FEMALE; HAPLOINSUFFICIENCY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROTO-ONCOGENE PROTEINS; SEQUENCE DELETION; TRANSLOCATION, GENETIC;

EID: 84865854071     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.03.004     Document Type: Article

References (27)

1. Levine R.L., Carroll M. A common genetic mechanism in malignant bone marrow diseases. N Engl J Med 2009, 360:2355-2357.
2. Mohamedali A.M., Smith A.E., Gaken J., et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009, 27:4002-4006.
3. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancer. N Engl J Med 2009, 360:2289-2301.
4. Viguié F., Aboura A., Bouscary D., et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement?. Leukemia 2005, 19:1411-1415.
5. Mohamedali A., Gäken J., Twine N.A., et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007, 110:3365-3373.
6. Gondek L.P., Haddad A.S., O'Keefe C.L., et al. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp Hematol 2007, 35:1728-1738.
7. Gondek L.P., Tiu R., O'Keefe C.L., et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 111:1534-1542.
8. Starczynowski D.T., Vercauteren S., Telenius A., et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008, 112:3412-3424.
9. Jankowska A.M., Szpurka H., Tiu R.V., et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113:6403-6410.
10. Kohlmann A., Grossmann V., Klein H.U., et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS and RUNX1. J Clin Oncol 2010, 28:3858-3865.
11. Smith A.E., Mohamedali A.M., Kulasekararaj A., et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no define prognostic value. Blood 2010, 116:3923-3932.
12. Tefferi A., Lim K.H., Levine R. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 361:1117.
13. Tefferi A., Pardanani A., Lim K.H., et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009, 23:905-911.
14. Tefferi A., Levine R.L., Lim K.H., et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23:900-904.
15. Kosmider O., Gelsi-Boyer V., Cheok M., et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009, 114:3285-3291.
16. Kosmider O., Gelsi-Boyer V., Ciudad M., et al. TET2 mutation is a frequent and adverse event in chronic myelomocytic leukaemia. Haematologica 2009, 94:1676-1681.
17. Langemeijer S.M.C., Kuiper R.P., Berends M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838-842.
18. Hussein K., Abdel-Wahab O., Lasho T.L., et al. Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. Am J Hematol 2010, 85:81-83.
19. Bacher U., Weissmann S., Kohlmann A., et al. TET2 deletions are recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele. Br J Haematol 2002, 156:67-75.
20. Couronné L., Lippert E., Andrieux J., et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 2010, 24:201-203.
21. Nibourel O., Kosmider O., Cheok M., et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010, 116:1132-1135.
22. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours 2008, Volume 2. IARC, Geneva.
23. Bernasconi P., Klersy C., Boni M., et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 2005, 19:1424-1431.
24. ISCN 2009: an international system for human cytogenetic nomenclature 2009, Karger, Basel. L.G. Shaffer, M.L. Slovak, L.J. Campbell (Eds.).
25. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer. Available at: accessed February 21, 2012. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
26. Tefferi A., Lim K.H., Abdel-Wahab O., et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009, 23:1343-1345.
27. Mallo M., Osca G., Solòrzano J., et al. TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study. Haematologica 2010, 95:1798-1800.